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Editorial Comment
Serum Lp(a) and diabetes mellitus increase the risk of car-
diovascular diseases (CVD). However, the relationship between 
serum Lp(a) and diabetes is poorly characterized, and it is a sub-
ject of debate as to whether they are independently or causally 
associated (1).
One of the atherogenic mechanisms in hyperglycemia is 
based on enhanced inflammation. Diabetes is associated with 
increased vascular production of reactive oxygen species (ROS), 
which causes premature cell apoptosis via reduction of endo-
thelial nitric oxide (NO), resulting in decreased smooth muscle 
relaxation and antiatherogenic properties, including decreased 
platelet aggregation and adhesion inhibition (1).
Another important atherogenic mechanism is the lipid 
fractions effect. Diabetic dyslipidemia consists of elevated 
triglyceride-rich lipoproteins (VLDLs) and VLDL remnants and 
low HDL-C levels. LDL particles are converted to smaller, more 
atherogenic lipoproteins known as “small-dense LDLs.” Dia-
betic dyslipidemia is due to insulin resistance and hypergly-
cemia. The diminished insulin action increases ApoB synthe-
sis, and the end products of this process are small-dense LDL 
particles with reduced LDL receptor-binding affinity, greater 
penetration in the arterial wall, and increased oxidation sus-
ceptibility, leading to atherogenesis. The Strong Heart Study 
showed that there is a stepwise decrease in LDL size ac-
cording to diabetic status. This association is more striking in 
women than in men (1).
Vergles (1) demonstrated the influence of hypertriglyceri-
demia and obesity in men and women with T2DM. The HDL2-
C levels were significantly lower in the presence of one/both 
factors, while in their absence, HDL2-C levels in the diabetics 
were not significantly different from those in the controls. These 
functionally-defective small-dense HDLs are characterized with 
defective ApoA1, prone to degradation and rapid renal elimina-
tion. This leads to low HDL-C levels in T2DM (1).
Lp(a) is a serum lipoprotein characterized by the pres-
ence of glycoprotein(a) linked to apoprotein B-100. Lp(a) is a 
poor ligand for the LDL receptors. The amino acid sequence of 
apoprotein(a) is found to be similar to that of the human plas-
minogen, which supports the hypothesis that the increased risk 
of premature atherosclerosis and thrombosis associated with 
elevated Lp(a) levels rises from the molecular mimicry of plas-
minogen by apo(a).
Studies regarding the association of Lp(a) levels and diabetes 
are contradictory. There are few T2DM studies with lower Lp(a) in 
diabetics compared with non-diabetics. Chico (3) found no differ-
ence in the mean Lp(a) concentration between diabetic and non-
diabetic subjects. In contrast, Ding et al. (2) reported that Lp(a) 
concentrations seem inversely associated with the prevalence 
of T2DM, prediabetes, insulin resistance, and hyperinsulinemia. 
Arauz (3) found a higher mean Lp(a) concentration in a group of 
T1DM and T2DM subjects but found no association of glycated he-
moglobin and Lp(a) in T2DM subjects. In the Singla et al. (3) study, 
Lp(a) levels were higher in diabetic patients but showed no associ-
ation with the degree of glycemic control. The elevated Lp(a) levels 
did not reflect the glycemic status and were also independent of 
increased LDL: HDL ratio, suggesting different metabolic pathways 
between LDL and Lp(a). Smaoui et al. (4) found no correlation of 
Lp(a) and glycemic control in Tunisian patients with T2DM. Posi-
tive correlations were observed between the Lp(a) levels and total 
and LDL-C in all diabetic patients, particularly in diabetic men. Un-
lühizarci found not only an association between T2DM and Lp(a) 
but also identified that the diabetic patients with gangrenous foot 
lesions were those with the highest level of Lp(a) (5).
Therefore, it can be agreed that there is no consensus in the 
present data as to whether Lp(a) and T2D are independently or 
causally associated with CVD risk.
The possible association of Lp(a) levels and metabolic and 
glycemic control is a major point of interest because the serum 
concentrations of apoprotein(a) and Lp(a) were found to be, to a 
large extent, genetically determined (1).
According to Fonseca et al. (6), excellent glycemic control 
per se does not equally impact nontraditional CVD risk factors, 
but various diabetes medications have different effects. HDL-
C was decreased with basal insulin and pioglitazone, whereas 
Lp(a) was increased with basal insulin therapy alone. Sánchez-
Quesada et al. (7) report that improved glycemic control in pa-
tients with T2DM has positive lipid profile effects, such as a 
significant reduction in nonesterified fatty acids and ApoB con-
centration, increased LDL size, and decreased electronegative 
LDL proportion. Similarly, the effect of resistant training on CVD 
risk factors in patients with T2DM is such that reduces glycemic 
indexes, decreases insulin resistance, downregulates ApoB lev-
els, and decreases ApoB/ApoA-I ratio, but does not lead to an 
alteration in ApoA-I, Lp(a), hs-CRP, and fibrinogen (8).
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Therefore, until we have a more definite conclusion, Kishitani 
et al. (9) besides fasting plasma glucose, HbA1c, and OGTT, rec-
ommend a set of additional biomarkers, such as GAD antibody, 
IA-2 antibody, IRI measurement, HOMA-R, HOMA-beta, small-
dense LDL-C, and RLP-C. Besides conventional lipid analyses, 
Lp(a) measuring has a significant role in this set of biomarkers 
and is recommended for patients with metabolic syndrome, im-
paired glucose tolerance, and diabetes.
Marija Vavlukis
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